➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Vadimezan

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Vadimezan?

Vadimezan is an investigational drug.

There have been 4 clinical trials for Vadimezan. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2010.

The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Novartis Pharmaceuticals, Swiss Group for Clinical Cancer Research, and University of Glasgow.

Recent Clinical Trials for Vadimezan
Paclitaxel, Carboplatin, and Dimethylxanthenone Acetic Acid in Treating Patients With Extensive-Stage Small Cell Lung CancerSwiss Group for Clinical Cancer ResearchPhase 2
Safety and Pharmacokinetics of ASA404 When Given Together With Fluvoxamine, a Selective Serotonin Receptor Reuptake Inhibitor and CYP1A2 InhibitorNovartis PharmaceuticalsPhase 1
Safety and Tolerability of ASA404 Administered in Combination With Docetaxel in Japanese Patients With Solid TumorsNovartis PharmaceuticalsPhase 1

See all Vadimezan clinical trials

Clinical Trial Summary for Vadimezan

Top disease conditions for Vadimezan
Top clinical trial sponsors for Vadimezan

See all Vadimezan clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.